Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

NASDAQ:CNTX

Context Therapeutics Inc.

Last Close

1.43

29/04 13:47

Market Cap

22.51M

Beta: -

Volume Today

11.90K

Avg: 99.97K

PE Ratio

−0.80

PFCF: −0.90

Filings Not Available

Please Sign In To Use The Chat